Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM

BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced five-year follow-up data from CARTITUDE-2 Cohort A (n=20) evaluating CARVYKTI(®) (ciltacabtagene autoleucel; cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) after one to three prior lines of therapy after a median follow-up of 60.7 months. These data were presented today at the 2026 International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland (Abstract #PA-288).